Cargando…
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
We show that variability in general levels of drug sensitivity in pre-clinical cancer models confounds biomarker discovery. However, using a very large panel of cell lines, each treated with many drugs, we could estimate a general level of sensitivity to all drugs in each cell line. By conditioning...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031330/ https://www.ncbi.nlm.nih.gov/pubmed/27654937 http://dx.doi.org/10.1186/s13059-016-1050-9 |